Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Oliver

Nurse Practitioner, Gerontology Jasper, AL Nurse Practitioner

NPI 1255725917 CMS profile 11151750

2201 N Airport Rd, Jasper, AL 35504

Open in the dashboard

General payments

$5,029

296 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Oliver of Jasper, AL is reported in the CMS Open Payments database as having received $5,029 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,579 132
2022 General $443 27
2021 General $2,007 137

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Oliver
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Tiffany Oliver were reported at $2,579. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Tiffany Oliver Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,007 $133 $44–$396 $132
2022 $443 $142 $48–$452 $149
2023 $0 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $2,579 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $794 44 payments
  2. AbbVie, Inc. $780 53 payments
  3. AstraZeneca Pharmaceuticals LP $466 26 payments
  4. Pfizer Inc. $295 15 payments
  5. GlaxoSmithKline, LLC. $294 21 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $223 14 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $182 9 payments
  8. Ardelyx, Inc. $161 7 payments
  9. Lilly USA, LLC $128 7 payments
  10. Amgen Inc. $125 7 payments
  11. Other $1,581 93 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,015 295 payments
  2. Education $14 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $493 24 payments
  2. RYBELSUS $467 23 payments
  3. UBRELVY $339 21 payments
  4. TRELEGY ELLIPTA $267 19 payments
  5. VRAYLAR $250 20 payments
  6. Wegovy $219 13 payments
  7. XIFAXAN $210 13 payments
  8. FARXIGA $201 9 payments
  9. QULIPTA $189 10 payments
  10. NURTEC ODT $189 9 payments
  11. Other $3,373 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record